The European journal of contraception & reproductive health care : the official journal of the European Society of ContraceptionMar 20, 2026

How drugs that activate GLP-1 receptors may affect fertility, birth control, and pregnancy

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Mar 21, 2026

Abstract

GLP-1 receptor agonists (GLP-1 RAs) may significantly improve spontaneous pregnancy rates in obese women with polycystic ovary syndrome (PCOS).

Weight reduction and enhanced insulin sensitivity from GLP-1 RAs are associated with improved fertility outcomes in women with PCOS.
Gastrointestinal side effects of GLP-1 RAs could theoretically affect the absorption of oral contraceptives.
Animal studies suggest potential risks to fetal development, and limited human data indicate a need for washout periods before conception.
In men, metabolic improvements from GLP-1 RAs may indirectly enhance reproductive parameters.
Non-oral hormonal methods and long-acting reversible contraception may be more reliable contraceptive options during GLP-1 RA treatment due to gastrointestinal side effects.

Simplified

OBJECTIVE: This debate paper aims to examine the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), whose use in obesity and diabetes management has rapidly expanded, on fertility, contraceptive efficacy, and pregnancy outcomes in reproductive-aged individuals, and to provide evidence-based clinical guidance.

MAIN ARGUMENTS/EVIDENCE: GLP-1 RAs improve fertility in obese women with polycystic ovary syndrome (PCOS) through weight reduction and enhanced insulin sensitivity, meta-analyses demonstrated significantly higher spontaneous pregnancy rates. However, gastrointestinal side effects may theoretically compromise the absorption of oral contraceptives. Animal studies indicate potential foetal risks, and limited human data support discontinuation before conception with appropriate washout periods (2-4 weeks for short-acting agents, 8 weeks for semaglutide and tirzepatide). In men, metabolic improvements may indirectly enhance reproductive parameters. From a contraceptive perspective, non-oral hormonal methods and long-acting reversible contraception may represent more reliable options during treatment, particularly in the presence of gastrointestinal side effects that could compromise oral drug absorption.

CONCLUSIONS: GLP-1 RAs are valuable adjuncts in managing obesity-related infertility, particularly in patients with PCOS. Clinicians must counsel patients regarding contraceptive reliability during treatment, ensure adequate washout before attempting conception, and recognise that while fertility benefits are well documented, pregnancy safety data remain limited.

Full Text

Full text is available at the source.

View Full Text ↗

How drugs that activate GLP-1 receptors may affect fertility, birth control, and pregnancy

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief